MedPath
FDA Approval

TAZICEF

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Hospira, Inc.
DUNS: 141588017
Effective Date
March 10, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Ceftazidime(6 g in 1 1)

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

TAZICEF

Product Details

NDC Product Code
0409-5086
Application Number
ANDA062662
Marketing Category
ANDA (C73584)
Route of Administration
INTRAVENOUS
Effective Date
March 10, 2023
Code: 9M416Z9QNRClass: ACTIMQuantity: 6 g in 1 1
SODIUM CARBONATEInactive
Code: 45P3261C7TClass: IACTQuantity: 708 mg in 1 1
© Copyright 2025. All Rights Reserved by MedPath
TAZICEF - FDA Approval | MedPath